Open AccessOnce-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly
Author(s) -
Władysław Sułowicz,
Francesco Locatelli,
JeanPhilippe Ryckelynck,
József Balla,
Botond Csiky,
Kevin Harris,
Patricia Ehrhard,
Ulrich Beyer
Publication year - 2007
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.03631006
Subject(s) - medicine , anemia , kidney disease , erythropoietin , hemoglobin , epoetin alfa , dialysis , confidence interval , peritoneal dialysis , gastroenterology , urology , surgery
C.E.R.A., a continuous erythropoietin receptor activator, is in development to provide anemia correction and stable maintenance of hemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease (CKD). This study examined its efficacy and safety when administered up to once monthly in patients who have CKD and are on dialysis and randomly convert directly from epoetin alpha or beta one to three times weekly.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom